<DOC>
	<DOCNO>NCT02038569</DOCNO>
	<brief_summary>An international , multi-centre , prospective , non-controlled , open , single-group , 8-week trial adolescent subject ( age 12 16 year , 11 month ) scalp body psoriasis .</brief_summary>
	<brief_title>Effect Calcipotriol Plus Betamethasone Dipropionate Gel HPA Axis Calcium Metabolism Adolescent Subjects ( Aged 12 16 Years , 11 Months ) With Scalp Body Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Inclusion Criteria ( subject ) : Clinical sign psoriasis vulgaris scalp body ( trunk and/or limb ) At SV2 Visit 1 , clinical diagnosis scalp body ( trunk and/or limb ) psoriasis : extent 10 35 % body surface area ( exclude psoriatic lesion face sensitive area . Sensitive area include armpit , groin , breast skin fold around genitals buttock ) , least moderate severity accord investigator 's global assessment disease severity body . A serum albumincorrected calcium level upper reference limit SV2 Inclusion Criteria ( subject perform HPA axis assessment ) : At SV2 Visit 1 , clinical diagnosis scalp psoriasis : equal 20 % scalp area , least moderate severity accord investigator 's global assessment disease severity scalp . Subjects normal HPA axis function SV2 include serum cortisol concentration 5 mcg/dl ACTH challenge serum cortisol concentration 18 mcg/dl 30 minute ACTH challenge . Inclusion Criteria ( subject perform HPA axis assessment ) : At SV2 Visit 1 , clinical diagnosis scalp psoriasis : equal 10 % scalp area , least moderate severity accord investigator 's global assessment disease severity scalp . Exclusion Criteria ( subject ) : Systemic treatment biological therapy ( market market ) , possible effect scalp and/or body psoriasis within follow time period prior Visit 1 trial : etanercept within 4 week prior Visit 1 adalimumab , infliximab within 2 month prior Visit 1 ustekinumab within 4 month prior Visit 1 experimental product within 4 weeks/5 halflives ( whichever longer ) prior Visit 1 Systemic treatment therapy biologicals , possible effect scalp and/or body psoriasis ( e.g. , retinoids , immunosuppressant , PUVA ) within 4 week prior Visit 1 ( Day 0 ) trial . UVB therapy within 2 week prior Visit 1 trial . Any topical treatment scalp body ( except emollient nonsteroid medicate shampoo ) within 2 week prior Visit 1 trial . Systemic calcium , vitamin D supplement , antacid , diuretic , antiepileptic , diphosphonates calcitonin within 4 week prior SV2 trial . Planned initiation , change , concomitant medication could affect psoriasis ( e.g. , betablockers , chloroquine , lithium , ACE inhibitor ) trial . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Subjects follow condition present treatment area scalp and/or body : viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , acne rosacea , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer wound . Other inflammatory skin disease may confound evaluation scalp and/or body psoriasis . Planned excessive exposure sun trial may affect scalp and/or body psoriasis . Known suspect severe renal insufficiency severe hepatic disorder . Known suspect disorder calcium metabolism associate hypercalcaemia . Any clinically significant abnormality follow review screen laboratory test ( blood urine sample ) , physical examination blood pressure/heart rate measurement perform SV2 . Current participation interventional clinical trial . Previously enrol trial . Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within month prior SV1 longer , class substance require longer washout define ( e.g. , biological treatment ) . Subjects parent ( ) legal guardian know suspect unlikely comply Clinical Trial Protocol ( e.g. , alcoholism , drug dependency psychotic state ) . Females pregnant , childbearing potential wishing become pregnant trial , breastfeed . Females childbearing potential positive pregnancy test SV2 . Subject ( partner ) use adequate method contraception accord national requirement . Exclusion Criteria ( subject perform HPA axis assessment ) A history serious allergy , allergic asthma serious allergic skin rash . Known suspected hypersensitivity component CORTROSYNÂ® ( include ACTH/cosyntropin/tetracosactide ) Systemic treatment corticosteroid ( include inhale nasal steroid ) within 12 week prior SV2 trial . Topical treatment corticosteroid within 2 week prior SV2 trial . Oestrogen therapy ( include contraceptive ) medication know affect cortisol level level HPA axis integrity within 4 week prior SV2 trial . Enzymatic inductor ( e.g. , barbiturate , phenytoin , rifampicin ) within 4 week prior SV2 trial . Systemic topical cytochrome P450 inhibitor ( e.g. , ketoconazole , itraconazole , metronidazole ) within 4 week prior SV2 trial . Topical ketoconazole 2 week prior SV2 . Hypoglycemic sulfonamide within 4 week prior SV2 trial . Antidepressive medication within 4 week prior SV2 trial . Known suspected endocrine disorder may affect result ACTH challenge test . Clinical sign symptoms Cushing 's disease Addison 's disease . Subjects diabetes mellitus . Known suspected cardiac condition . Not follow nocturnal sleep pattern .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>